首页 > 最新文献

Cancer Radiotherapie最新文献

英文 中文
A prospective observational study evaluating two patient immobilisation methods in lung stereotactic radiotherapy 一项前瞻性观察研究,评估肺立体定向放射治疗中的两种患者固定方法。
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-06-01 DOI: 10.1016/j.canrad.2023.08.012
S. Boisbouvier, I. Martel-Lafay, R. Tanguy, M. Ayadi-Zahra

Purpose

The main objective of this study was to assess inter- and intrafraction errors for two patient immobilisation devices in the context of lung stereotactic body radiation therapy: a vacuum cushion and a simple arm support.

Materials and methods

Twenty patients who were treated with lung stereotactic body radiation therapy in supine position with arms above their head were included in the study. Ten patients were setup in a vacuum cushion (Bluebag™, Elekta) and ten other patients with a simple arm support (Posirest™, Civco). A pretreatment four-dimensional cone-beam computed tomography and a post-treatment three-dimensional cone-beam computed tomography were acquired to compare positioning and immobilisation accuracy. Based on a rigid registration with the planning computed tomography on the spine at the target level, translational and rotational errors were reported.

Results

The median number of fractions per treatment was 5 (range: 3–10). Mean interfraction errors based on 112 four-dimensional cone-beam computed tomographies were similar for both setups with deviations less than or equal to 1.3 mm in lateral and vertical direction and 1.2° in roll and yaw. For longitudinal translational errors, mean interfraction errors were 0.7 mm with vacuum cushion and –3.9 mm with arm support. Based on 111 three-dimensional cone-beam computed tomographies, mean lateral, longitudinal and vertical intrafraction errors were –0.1 mm, –0.2 mm and 0.0 mm respectively (SD: 1.0, 1.2 and 1.0 mm respectively) for the patients setup with vacuum cushion, and mean vertical, longitudinal and lateral intrafraction errors were –0.3 mm, –0.7 mm and 0.1 mm respectively (SD: 2.3, 1.8 and 1.4 mm respectively) for the patients setup with arm support. Intrafraction errors means were not statistically different between both positions but standard deviations were statistically larger with arm support.

Conclusion

The results of our study showed similar inter and intrafraction mean deviations between both positioning but a large variability in intrafraction observed with arm support suggested a more accurate immobilization with vacuum cushion.

目的:本研究的主要目的是评估肺立体定向体放射治疗中两种患者固定装置(真空垫和简易手臂支撑)的分量间和分量内误差:研究对象包括20名接受肺立体定向体放射治疗的患者,患者仰卧位,双臂举过头顶。其中十名患者使用真空垫(Bluebag™,Elekta),另外十名患者使用简易手臂支撑(Posirest™,Civco)。为了比较定位和固定的准确性,对患者进行了治疗前四维锥形束计算机断层扫描和治疗后三维锥形束计算机断层扫描。根据与目标水平脊柱计划计算机断层扫描的刚性登记,报告了平移和旋转误差:结果:每次治疗的分数中位数为 5(范围:3-10)。基于112张四维锥形束计算机断层扫描的平均牵引误差在两种设置下相似,横向和纵向偏差小于或等于1.3毫米,滚动和偏航偏差小于或等于1.2°。在纵向平移误差方面,使用真空缓冲器时的平均折射误差为 0.7 毫米,使用手臂支撑时的平均折射误差为-3.9 毫米。根据111张三维锥束计算机断层扫描图,使用真空垫的患者的横向、纵向和垂直方向的平均折射内误差分别为-0.1毫米、-0.2毫米和0.0毫米(标度分别为1.0、1.2和1.0毫米),而使用手臂支撑的患者的垂直、纵向和横向的平均折射内误差分别为-0.3毫米、-0.7毫米和0.1毫米(标度分别为2.3、1.8和1.4毫米)。两种体位的屈光内误差均值在统计学上没有差异,但标准差在统计学上手臂支撑体位的误差更大:我们的研究结果表明,两种体位的屈光间和屈光内平均偏差相似,但手臂支撑体位的屈光内偏差较大,这表明使用真空垫固定更为精确。
{"title":"A prospective observational study evaluating two patient immobilisation methods in lung stereotactic radiotherapy","authors":"S. Boisbouvier,&nbsp;I. Martel-Lafay,&nbsp;R. Tanguy,&nbsp;M. Ayadi-Zahra","doi":"10.1016/j.canrad.2023.08.012","DOIUrl":"10.1016/j.canrad.2023.08.012","url":null,"abstract":"<div><h3>Purpose</h3><p>The main objective of this study was to assess inter- and intrafraction errors for two patient immobilisation devices in the context of lung stereotactic body radiation therapy: a vacuum cushion and a simple arm support.</p></div><div><h3>Materials and methods</h3><p>Twenty patients who were treated with lung stereotactic body radiation therapy in supine position with arms above their head were included in the study. Ten patients were setup in a vacuum cushion (Bluebag™, Elekta) and ten other patients with a simple arm support (Posirest™, Civco). A pretreatment four-dimensional cone-beam computed tomography and a post-treatment three-dimensional cone-beam computed tomography were acquired to compare positioning and immobilisation accuracy. Based on a rigid registration with the planning computed tomography on the spine at the target level, translational and rotational errors were reported.</p></div><div><h3>Results</h3><p>The median number of fractions per treatment was 5 (range: 3–10). Mean interfraction errors based on 112 four-dimensional cone-beam computed tomographies were similar for both setups with deviations less than or equal to 1.3<!--> <!-->mm in lateral and vertical direction and 1.2° in roll and yaw. For longitudinal translational errors, mean interfraction errors were 0.7<!--> <!-->mm with vacuum cushion and –3.9<!--> <!-->mm with arm support. Based on 111 three-dimensional cone-beam computed tomographies, mean lateral, longitudinal and vertical intrafraction errors were –0.1<!--> <!-->mm, –0.2<!--> <!-->mm and 0.0<!--> <!-->mm respectively (SD: 1.0, 1.2 and 1.0<!--> <!-->mm respectively) for the patients setup with vacuum cushion, and mean vertical, longitudinal and lateral intrafraction errors were –0.3<!--> <!-->mm, –0.7<!--> <!-->mm and 0.1<!--> <!-->mm respectively (SD: 2.3, 1.8 and 1.4<!--> <!-->mm respectively) for the patients setup with arm support. Intrafraction errors means were not statistically different between both positions but standard deviations were statistically larger with arm support.</p></div><div><h3>Conclusion</h3><p>The results of our study showed similar inter and intrafraction mean deviations between both positioning but a large variability in intrafraction observed with arm support suggested a more accurate immobilization with vacuum cushion.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141319269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Palliative radiotherapy: New prognostic factors for patients with bone metastasis 姑息放射治疗:骨转移患者的新预后因素。
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-06-01 DOI: 10.1016/j.canrad.2023.09.003
I.N. Steinvoort-Draat, L. Otto-Vollaard, S. Quint, J.L. Tims, I.M.N. de Pree, J.J. Nuyttens

Purpose

Many cancer patients develop bone metastases, however the prognosis of overall survival differs. To provide an optimal treatment for these patients, especially towards the end of life, a reliable prediction of survival is needed. The goal of this study was to find new clinical factors in relation to overall survival.

Materials and methods

Prospectively 22 clinical factors were collected from 734 patients. The Kaplan–Meier and Cox regression models were used.

Results

Most patients were diagnosed with lung cancer (29%), followed by prostate (19.8%) and breast cancer (14.7%). Median overall survival was 6.4 months. Fourteen clinical factors showed significance in the univariate analyses. In the multivariate analyses 6 factors were found to be significant for the overall survival: Karnofsky performance status, primary tumor, gender, total organs affected, morphine use and systemic treatment options after radiotherapy.

Conclusion

Morphine use and systemic treatment options after radiotherapy, Karnofsky performance status, primary tumor, gender and total organs affected are strong prediction factors on overall survival after palliative radiotherapy in patients with bone metastasis. These factors are easily applicable in the clinic.

目的:许多癌症患者都会发生骨转移,但总体生存期的预后却各不相同。为了给这些患者提供最佳治疗,尤其是在生命的最后阶段,需要对生存率进行可靠的预测。本研究的目的是找到与总生存率相关的新临床因素:前瞻性地收集了 734 名患者的 22 个临床因素。结果:大多数患者被确诊为肺癌,其中有 3 名患者被确诊为乳腺癌,有 1 名患者被确诊为肺癌,有 2 名患者被确诊为乳腺癌:结果:大多数患者被诊断为肺癌(29%),其次是前列腺癌(19.8%)和乳腺癌(14.7%)。中位总生存期为 6.4 个月。在单变量分析中,14个临床因素具有显著性。在多变量分析中,有6个因素对总生存期有显著影响:Karnofsky表现状态、原发肿瘤、性别、受影响器官总数、吗啡使用情况和放疗后的全身治疗方案:结论:吗啡的使用和放疗后的全身治疗方案、Karnofsky表现状态、原发肿瘤、性别和受累器官总数是骨转移患者姑息性放疗后总生存期的有力预测因素。这些因素很容易应用于临床。
{"title":"Palliative radiotherapy: New prognostic factors for patients with bone metastasis","authors":"I.N. Steinvoort-Draat,&nbsp;L. Otto-Vollaard,&nbsp;S. Quint,&nbsp;J.L. Tims,&nbsp;I.M.N. de Pree,&nbsp;J.J. Nuyttens","doi":"10.1016/j.canrad.2023.09.003","DOIUrl":"10.1016/j.canrad.2023.09.003","url":null,"abstract":"<div><h3>Purpose</h3><p>Many cancer patients develop bone metastases, however the prognosis of overall survival differs. To provide an optimal treatment for these patients, especially towards the end of life, a reliable prediction of survival is needed. The goal of this study was to find new clinical factors in relation to overall survival.</p></div><div><h3>Materials and methods</h3><p>Prospectively 22 clinical factors were collected from 734 patients. The Kaplan–Meier and Cox regression models were used.</p></div><div><h3>Results</h3><p>Most patients were diagnosed with lung cancer (29%), followed by prostate (19.8%) and breast cancer (14.7%). Median overall survival was 6.4<!--> <!-->months. Fourteen clinical factors showed significance in the univariate analyses. In the multivariate analyses 6 factors were found to be significant for the overall survival: Karnofsky performance status, primary tumor, gender, total organs affected, morphine use and systemic treatment options after radiotherapy.</p></div><div><h3>Conclusion</h3><p>Morphine use and systemic treatment options after radiotherapy, Karnofsky performance status, primary tumor, gender and total organs affected are strong prediction factors on overall survival after palliative radiotherapy in patients with bone metastasis. These factors are easily applicable in the clinic.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1278321824000581/pdfft?md5=faebc9b9aa82934282638c2c8e9998d5&pid=1-s2.0-S1278321824000581-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141319271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Consentement aux soins en radiothérapie [放射治疗护理中的知情同意]。
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-06-01 DOI: 10.1016/j.canrad.2024.04.001
C. Sire , A. Ducteil , J.-L. Lagrange , P. Maingon , F. Lorchel , I. Latorzeff , C. Hennequin , P. Giraud , T. Leroy , V. Vendrely , J.-M. Hannoun-Lévi , C. Chargari , N. Pourel , Y. Elhouat , J.-J. Mazeron , V. Marchesi , F. Huguet , É. Monpetit , D. Azria

Obtaining consent to care requires the radiation oncologist to provide loyal information and to ensure that the patient understands it. Proof of such an approach rests with the practitioner. The French Society for Radiation Oncology (SFRO) does not recommend the signature of a consent form by the patient but recommends that the radiation oncologist be able to provide all the elements demonstrating the reality of a complete information circuit.

要获得患者对治疗的同意,肿瘤放射医师必须提供忠实的信息,并确保患者理解这些信息。这种做法的证据在于从业者。法国放射肿瘤学会(SFRO)不建议患者在同意书上签字,但建议放射肿瘤医师能够提供所有要素,以证明完整信息回路的真实性。
{"title":"Consentement aux soins en radiothérapie","authors":"C. Sire ,&nbsp;A. Ducteil ,&nbsp;J.-L. Lagrange ,&nbsp;P. Maingon ,&nbsp;F. Lorchel ,&nbsp;I. Latorzeff ,&nbsp;C. Hennequin ,&nbsp;P. Giraud ,&nbsp;T. Leroy ,&nbsp;V. Vendrely ,&nbsp;J.-M. Hannoun-Lévi ,&nbsp;C. Chargari ,&nbsp;N. Pourel ,&nbsp;Y. Elhouat ,&nbsp;J.-J. Mazeron ,&nbsp;V. Marchesi ,&nbsp;F. Huguet ,&nbsp;É. Monpetit ,&nbsp;D. Azria","doi":"10.1016/j.canrad.2024.04.001","DOIUrl":"10.1016/j.canrad.2024.04.001","url":null,"abstract":"<div><p>Obtaining consent to care requires the radiation oncologist to provide loyal information and to ensure that the patient understands it. Proof of such an approach rests with the practitioner. The French Society for Radiation Oncology (SFRO) does not recommend the signature of a consent form by the patient but recommends that the radiation oncologist be able to provide all the elements demonstrating the reality of a complete information circuit.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141312499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence solution to accelerate the acquisition of MRI images: Impact on the therapeutic care in oncology in radiology and radiotherapy departments 加速磁共振成像图像采集的人工智能解决方案:对放射科和放疗科肿瘤治疗护理的影响。
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-06-01 DOI: 10.1016/j.canrad.2023.11.004
R. Lemaire , C. Raboutet , T. Leleu , C. Jaudet , L. Dessoude , F. Missohou , Y. Poirier , P.-Y. Deslandes , A. Lechervy , J. Lacroix , I. Moummad , S. Bardet , J. Thariat , D. Stefan , A. Corroyer-Dulmont

Purpose

MRI is essential in the management of brain tumours. However, long waiting times reduce patient accessibility. Reducing acquisition time could improve access but at the cost of spatial resolution and diagnostic quality. A commercially available artificial intelligence (AI) solution, SubtleMR™, can increase the resolution of acquired images. The objective of this prospective study was to evaluate the impact of this algorithm that halves the acquisition time on the detectability of brain lesions in radiology and radiotherapy.

Material and methods

The T1/T2 MRI of 33 patients with brain metastases or meningiomas were analysed. Images acquired quickly have a matrix divided by two which halves the acquisition time. The visual quality and lesion detectability of the AI images were evaluated by radiologists and radiation oncologist as well as pixel intensity and lesions size.

Results

The subjective quality of the image is lower for the AI images compared to the reference images. However, the analysis of lesion detectability shows a specificity of 1 and a sensitivity of 0.92 and 0.77 for radiology and radiotherapy respectively. Undetected lesions on the IA image are lesions with a diameter less than 4 mm and statistically low average gadolinium-enhancement contrast.

Conclusion

It is possible to reduce MRI acquisition times by half using the commercial algorithm to restore the characteristics of the image and obtain good specificity and sensitivity for lesions with a diameter greater than 4 mm.

目的:核磁共振成像对脑肿瘤的治疗至关重要。然而,漫长的等待时间降低了患者的可及性。缩短采集时间可以改善就诊情况,但代价是空间分辨率和诊断质量下降。市售的人工智能(AI)解决方案 SubtleMR™ 可以提高采集图像的分辨率。这项前瞻性研究的目的是评估这种将采集时间减半的算法对放射学和放射治疗中脑部病变可探测性的影响:对 33 名脑转移瘤或脑膜瘤患者的 T1/T2 MRI 进行了分析。快速采集的图像矩阵除以二,采集时间减半。放射科医生和放射肿瘤科医生对 AI 图像的视觉质量和病灶可探测性以及像素强度和病灶大小进行了评估:结果:与参考图像相比,人工智能图像的主观质量较低。然而,对病灶可探测性的分析表明,放射科和放疗科的特异性为 1,灵敏度分别为 0.92 和 0.77。IA 图像上未检测到的病灶是指直径小于 4 毫米且平均钆增强对比度较低的病灶:使用商业算法恢复图像特征,可以将 MRI 采集时间缩短一半,并对直径大于 4 毫米的病变获得良好的特异性和灵敏度。
{"title":"Artificial intelligence solution to accelerate the acquisition of MRI images: Impact on the therapeutic care in oncology in radiology and radiotherapy departments","authors":"R. Lemaire ,&nbsp;C. Raboutet ,&nbsp;T. Leleu ,&nbsp;C. Jaudet ,&nbsp;L. Dessoude ,&nbsp;F. Missohou ,&nbsp;Y. Poirier ,&nbsp;P.-Y. Deslandes ,&nbsp;A. Lechervy ,&nbsp;J. Lacroix ,&nbsp;I. Moummad ,&nbsp;S. Bardet ,&nbsp;J. Thariat ,&nbsp;D. Stefan ,&nbsp;A. Corroyer-Dulmont","doi":"10.1016/j.canrad.2023.11.004","DOIUrl":"10.1016/j.canrad.2023.11.004","url":null,"abstract":"<div><h3>Purpose</h3><p>MRI is essential in the management of brain tumours. However, long waiting times reduce patient accessibility. Reducing acquisition time could improve access but at the cost of spatial resolution and diagnostic quality. A commercially available artificial intelligence (AI) solution, SubtleMR™, can increase the resolution of acquired images. The objective of this prospective study was to evaluate the impact of this algorithm that halves the acquisition time on the detectability of brain lesions in radiology and radiotherapy.</p></div><div><h3>Material and methods</h3><p>The T1/T2 MRI of 33 patients with brain metastases or meningiomas were analysed. Images acquired quickly have a matrix divided by two which halves the acquisition time. The visual quality and lesion detectability of the AI images were evaluated by radiologists and radiation oncologist as well as pixel intensity and lesions size.</p></div><div><h3>Results</h3><p>The subjective quality of the image is lower for the AI images compared to the reference images. However, the analysis of lesion detectability shows a specificity of 1 and a sensitivity of 0.92 and 0.77 for radiology and radiotherapy respectively. Undetected lesions on the IA image are lesions with a diameter less than 4<!--> <!-->mm and statistically low average gadolinium-enhancement contrast.</p></div><div><h3>Conclusion</h3><p>It is possible to reduce MRI acquisition times by half using the commercial algorithm to restore the characteristics of the image and obtain good specificity and sensitivity for lesions with a diameter greater than 4<!--> <!-->mm.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141312500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is neoadjuvant folfox an effective treatment only in a very selected favorable subgroup of locally advanced rectal cancer? 新辅助 Folfox 是否仅对极个别局部晚期直肠癌的有利亚组有效?
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-06-01 DOI: 10.1016/j.canrad.2023.12.002
O. Riou , F. Castan , T. Conroy
{"title":"Is neoadjuvant folfox an effective treatment only in a very selected favorable subgroup of locally advanced rectal cancer?","authors":"O. Riou ,&nbsp;F. Castan ,&nbsp;T. Conroy","doi":"10.1016/j.canrad.2023.12.002","DOIUrl":"10.1016/j.canrad.2023.12.002","url":null,"abstract":"","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141319270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
La radiothérapie du cancer de la prostate augmente-t-elle le risque de seconds cancers ? [前列腺癌放射治疗会增加罹患第二种癌症的风险吗?]
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-06-01 DOI: 10.1016/j.canrad.2023.07.018
A. Boué-Raflé , A. Briens , S. Supiot , P. Blanchard , M. Baty , C. Lafond , I. Masson , G. Créhange , J.-M. Cosset , D. Pasquier , R. de Crevoisier

Purpose

The increased risk of second cancer after prostate radiotherapy is a debated clinical concern. The objective of the study was to assess the risk of occurrence of second cancers after prostate radiation therapy based on the analysis the literature, and to identify potential factors explaining the discrepancies in results between studies.

Materials and methods

A review of the literature was carried out, comparing the occurrence of second cancers in patients all presenting with prostate cancer, treated or not by radiation.

Results

This review included 30 studies reporting the occurrence of second cancers in 2,112,000 patients treated or monitored for localized prostate cancer, including 1,111,000 by external radiation therapy and 103,000 by brachytherapy. Regarding external radiation therapy, the average follow-up was 7.3 years. The majority of studies (80%) involving external radiation therapy, compared to no external radiation therapy, showed an increased risk of second cancers with a hazard ratio ranging from 1.13 to 4.9, depending on the duration of the follow-up. The median time to the occurrence of these second cancers after external radiotherapy ranged from 4 to 6 years. An increased risk of second rectal and bladder cancer was observed in 52% and 85% of the studies, respectively. Considering a censoring period of more than 10 years after irradiation, 57% and 100% of the studies found an increased risk of rectal and bladder cancer, without any impact in overall survival. Studies of brachytherapy did not show an increased risk of second cancer. However, these comparative studies, most often old and retrospective, had many methodological biases.

Conclusion

Despite numerous methodological biases, prostate external radiation therapy appears associated with a moderate increase in the risk of second pelvic cancer, in particular bladder cancer, without impacting survival. Brachytherapy does not increase the risk of a second cancer.

目的:前列腺放疗后患第二癌症的风险增加是一个备受争议的临床问题。本研究的目的是根据文献分析评估前列腺放疗后发生二次癌症的风险,并找出造成不同研究结果差异的潜在因素:对文献进行了回顾,比较了所有前列腺癌患者在接受或未接受放射治疗后发生二次癌症的情况:该综述包括30项研究,报告了211.2万名接受治疗或监测的局部前列腺癌患者的二次癌症发生率,其中111.1万名患者接受了体外放射治疗,10.3万名患者接受了近距离放射治疗。关于体外放射治疗,平均随访时间为 7.3 年。大多数(80%)涉及体外放射治疗的研究显示,与不进行体外放射治疗相比,二次癌症的风险增加,危险比从1.13到4.9不等,具体取决于随访时间的长短。体外放射治疗后发生二次癌症的中位时间为 4 至 6 年。分别有52%和85%的研究观察到直肠癌和膀胱癌的二次发病风险增加。考虑到照射后超过10年的普查期,57%和100%的研究发现直肠癌和膀胱癌的风险增加,但对总生存率没有任何影响。关于近距离放射治疗的研究并未显示罹患第二种癌症的风险增加。然而,这些比较研究多为陈旧的回顾性研究,存在许多方法上的偏差:结论:尽管存在许多方法上的偏差,前列腺体外放射治疗似乎会适度增加罹患第二种盆腔癌症(尤其是膀胱癌)的风险,但不会影响存活率。近距离放射治疗不会增加罹患第二种癌症的风险。
{"title":"La radiothérapie du cancer de la prostate augmente-t-elle le risque de seconds cancers ?","authors":"A. Boué-Raflé ,&nbsp;A. Briens ,&nbsp;S. Supiot ,&nbsp;P. Blanchard ,&nbsp;M. Baty ,&nbsp;C. Lafond ,&nbsp;I. Masson ,&nbsp;G. Créhange ,&nbsp;J.-M. Cosset ,&nbsp;D. Pasquier ,&nbsp;R. de Crevoisier","doi":"10.1016/j.canrad.2023.07.018","DOIUrl":"10.1016/j.canrad.2023.07.018","url":null,"abstract":"<div><h3>Purpose</h3><p>The increased risk of second cancer after prostate radiotherapy is a debated clinical concern. The objective of the study was to assess the risk of occurrence of second cancers after prostate radiation therapy based on the analysis the literature, and to identify potential factors explaining the discrepancies in results between studies.</p></div><div><h3>Materials and methods</h3><p>A review of the literature was carried out, comparing the occurrence of second cancers in patients all presenting with prostate cancer, treated or not by radiation.</p></div><div><h3>Results</h3><p>This review included 30 studies reporting the occurrence of second cancers in 2,112,000 patients treated or monitored for localized prostate cancer, including 1,111,000 by external radiation therapy and 103,000 by brachytherapy. Regarding external radiation therapy, the average follow-up was 7.3<!--> <!-->years. The majority of studies (80%) involving external radiation therapy, compared to no external radiation therapy, showed an increased risk of second cancers with a hazard ratio ranging from 1.13 to 4.9, depending on the duration of the follow-up. The median time to the occurrence of these second cancers after external radiotherapy ranged from 4 to 6<!--> <!-->years. An increased risk of second rectal and bladder cancer was observed in 52% and 85% of the studies, respectively. Considering a censoring period of more than 10 years after irradiation, 57% and 100% of the studies found an increased risk of rectal and bladder cancer, without any impact in overall survival. Studies of brachytherapy did not show an increased risk of second cancer. However, these comparative studies, most often old and retrospective, had many methodological biases.</p></div><div><h3>Conclusion</h3><p>Despite numerous methodological biases, prostate external radiation therapy appears associated with a moderate increase in the risk of second pelvic cancer, in particular bladder cancer, without impacting survival. Brachytherapy does not increase the risk of a second cancer.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141322226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating ChatGPT to test its robustness as an interactive information database of radiation oncology and to assess its responses to common queries from radiotherapy patients: A single institution investigation 对 ChatGPT 进行评估,以测试其作为放射肿瘤学互动信息数据库的稳健性,并评估其对放射治疗患者常见询问的回应:单一机构调查。
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-06-01 DOI: 10.1016/j.canrad.2023.11.005
V.K. Pandey , A. Munshi , B.K. Mohanti , K. Bansal , K. Rastogi

Purpose

Commercial vendors have created artificial intelligence (AI) tools for use in all aspects of life and medicine, including radiation oncology. AI innovations will likely disrupt workflows in the field of radiation oncology. However, limited data exist on using AI-based chatbots about the quality of radiation oncology information. This study aims to assess the accuracy of ChatGPT, an AI-based chatbot, in answering patients’ questions during their first visit to the radiation oncology outpatient department and test knowledge of ChatGPT in radiation oncology.

Material and methods

Expert opinion was formulated using a set of ten standard questions of patients encountered in outpatient department practice. A blinded expert opinion was taken for the ten questions on common queries of patients in outpatient department visits, and the same questions were evaluated on ChatGPT version 3.5 (ChatGPT 3.5). The answers by expert and ChatGPT were independently evaluated for accuracy by three scientific reviewers. Additionally, a comparison was made for the extent of similarity of answers between ChatGPT and experts by a response scoring for each answer. Word count and Flesch-Kincaid readability score and grade were done for the responses obtained from expert and ChatGPT. A comparison of the answers of ChatGPT and expert was done with a Likert scale. As a second component of the study, we tested the technical knowledge of ChatGPT. Ten multiple choice questions were framed with increasing order of difficulty – basic, intermediate and advanced, and the responses were evaluated on ChatGPT. Statistical testing was done using SPSS version 27.

Results

After expert review, the accuracy of expert opinion was 100%, and ChatGPT's was 80% (8/10) for regular questions encountered in outpatient department visits. A noticeable difference was observed in word count and readability of answers from expert opinion or ChatGPT. Of the ten multiple-choice questions for assessment of radiation oncology database, ChatGPT had an accuracy rate of 90% (9 out of 10). One answer to a basic-level question was incorrect, whereas all answers to intermediate and difficult-level questions were correct.

Conclusion

ChatGPT provides reasonably accurate information about routine questions encountered in the first outpatient department visit of the patient and also demonstrated a sound knowledge of the subject. The result of our study can inform the future development of educational tools in radiation oncology and may have implications in other medical fields. This is the first study that provides essential insight into the potentially positive capabilities of two components of ChatGPT: firstly, ChatGPT's response to common queries of patients at OPD visits, and secondly, the assessment of the radiation oncology knowledge base of ChatGPT.

目的:商业供应商已开发出人工智能(AI)工具,可用于生活和医学的各个方面,包括肿瘤放射学。人工智能的创新很可能会颠覆放射肿瘤学领域的工作流程。然而,关于使用基于人工智能的聊天机器人获取放射肿瘤学信息质量的数据还很有限。本研究旨在评估基于人工智能的聊天机器人 ChatGPT 在回答首次到放射肿瘤学门诊部就诊的患者问题时的准确性,并测试 ChatGPT 在放射肿瘤学方面的知识:使用门诊部实践中遇到的患者的十个标准问题,形成专家意见。就门诊部就诊患者的常见疑问对这十个问题进行了盲法专家鉴定,并在 ChatGPT 3.5 版(ChatGPT 3.5)上对相同的问题进行了评估。专家和 ChatGPT 的答案由三位科学评审员独立评估其准确性。此外,ChatGPT 和专家答案的相似程度也通过对每个答案的评分进行了比较。对专家和 ChatGPT 的回答进行了字数统计、Flesch-Kincaid 可读性评分和等级评定。通过李克特量表对 ChatGPT 和专家的答案进行了比较。作为研究的第二部分,我们测试了 ChatGPT 的技术知识。我们设计了十道选择题,难度依次为基础、中级和高级,并对 ChatGPT 的回答进行了评估。统计测试使用 SPSS 27 版本:经过专家评审,对于门诊部就诊中遇到的常规问题,专家意见的准确率为 100%,而 ChatGPT 的准确率为 80%(8/10)。专家意见和 ChatGPT 的答案在字数和可读性方面存在明显差异。在放射肿瘤学数据库评估的 10 道多选题中,ChatGPT 的准确率为 90%(10 选 9)。基础题有一个答案是错误的,而中级和困难题的所有答案都是正确的:结论:ChatGPT 为患者在首次门诊就诊时遇到的常规问题提供了相当准确的信息,同时也展示了对该主题的充分了解。我们的研究结果可为今后放射肿瘤学教育工具的开发提供参考,并可能对其他医学领域产生影响。这是第一项对 ChatGPT 两个组成部分的潜在积极功能提供重要见解的研究:首先是 ChatGPT 对患者在门诊就诊时常见问题的回答,其次是对 ChatGPT 放射肿瘤学知识库的评估。
{"title":"Evaluating ChatGPT to test its robustness as an interactive information database of radiation oncology and to assess its responses to common queries from radiotherapy patients: A single institution investigation","authors":"V.K. Pandey ,&nbsp;A. Munshi ,&nbsp;B.K. Mohanti ,&nbsp;K. Bansal ,&nbsp;K. Rastogi","doi":"10.1016/j.canrad.2023.11.005","DOIUrl":"10.1016/j.canrad.2023.11.005","url":null,"abstract":"<div><h3>Purpose</h3><p>Commercial vendors have created artificial intelligence (AI) tools for use in all aspects of life and medicine, including radiation oncology. AI innovations will likely disrupt workflows in the field of radiation oncology. However, limited data exist on using AI-based chatbots about the quality of radiation oncology information. This study aims to assess the accuracy of ChatGPT, an AI-based chatbot, in answering patients’ questions during their first visit to the radiation oncology outpatient department and test knowledge of ChatGPT in radiation oncology.</p></div><div><h3>Material and methods</h3><p>Expert opinion was formulated using a set of ten standard questions of patients encountered in outpatient department practice. A blinded expert opinion was taken for the ten questions on common queries of patients in outpatient department visits, and the same questions were evaluated on ChatGPT version 3.5 (ChatGPT 3.5). The answers by expert and ChatGPT were independently evaluated for accuracy by three scientific reviewers. Additionally, a comparison was made for the extent of similarity of answers between ChatGPT and experts by a response scoring for each answer. Word count and Flesch-Kincaid readability score and grade were done for the responses obtained from expert and ChatGPT. A comparison of the answers of ChatGPT and expert was done with a Likert scale. As a second component of the study, we tested the technical knowledge of ChatGPT. Ten multiple choice questions were framed with increasing order of difficulty – basic, intermediate and advanced, and the responses were evaluated on ChatGPT. Statistical testing was done using SPSS version 27.</p></div><div><h3>Results</h3><p>After expert review, the accuracy of expert opinion was 100%, and ChatGPT's was 80% (8/10) for regular questions encountered in outpatient department visits. A noticeable difference was observed in word count and readability of answers from expert opinion or ChatGPT. Of the ten multiple-choice questions for assessment of radiation oncology database, ChatGPT had an accuracy rate of 90% (9 out of 10). One answer to a basic-level question was incorrect, whereas all answers to intermediate and difficult-level questions were correct.</p></div><div><h3>Conclusion</h3><p>ChatGPT provides reasonably accurate information about routine questions encountered in the first outpatient department visit of the patient and also demonstrated a sound knowledge of the subject. The result of our study can inform the future development of educational tools in radiation oncology and may have implications in other medical fields. This is the first study that provides essential insight into the potentially positive capabilities of two components of ChatGPT: firstly, ChatGPT's response to common queries of patients at OPD visits, and secondly, the assessment of the radiation oncology knowledge base of ChatGPT.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141312520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival and toxicity after breast-conserving surgery and external beam reirradiation for localized ipsilateral breast tumour recurrence: A population-based study 局部同侧乳腺肿瘤复发的保乳手术和体外再照射术后的生存率和毒性:一项基于人群的研究。
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-06-01 DOI: 10.1016/j.canrad.2024.03.001
P. Loap, A. Fourquet, Y. Kirova

Purpose

Breast-conserving surgery followed by reirradiation for a localized ipsilateral breast tumour relapse may increase the radiation dose delivered to the heart and result in a greater risk of cardiac adverse events. This study aimed to compare the incidence of cardiac mortality in patients treated for a localized ipsilateral breast tumour relapse, either with breast-conserving surgery followed by reirradiation or with total mastectomy between 2000 and 2020.

Materials and methods

All patients treated for a primary non-metastatic breast cancer with breast-conserving surgery and adjuvant radiotherapy were identified in the Surveillance, Epidemiology, and End Results (SEER) program database, and those who subsequently experienced a localized ipsilateral breast tumour relapse treated with breast-conserving surgery and reirradiation (“BCS + ReRT” group, n = 239) or with total mastectomy (“TM” group, n = 3127) were included. The primary objective was to compare the cardiac mortality rate between the patients who underwent breast-conserving surgery followed by reirradiation and total mastectomy. Secondary endpoints were overall survival and cancer specific survival.

Results

Cardiac mortality was significantly higher in patients treated with breast-conserving surgery followed by reirradiation (hazard ratio [HR]: 2.40, 95% confidence interval [95% CI]: 1.19–4.86, P = 0.006) in univariate analysis; non-statistically significant differences were observed after adjusting for age, laterality and chemotherapy on multivariate analysis (HR: 1.96, 95% CI: 0.96–3.94, P = 0.067), age being the only confounding factor. A non-statistically significant difference towards lower overall survival was observed in patients who had breast-conserving surgery followed by reirradiation compared with those who underwent total mastectomy (HR: 1.37, 95% CI: 0.98–1.90, P = 0.066), and no differences were observed in terms of cancer specific survival (HR: 1.01, 95% CI: 0.56–1.82, P = 0.965).

Conclusion

In this study, the incidence of cardiac mortality was low, and breast-conserving surgery followed by reirradiation did not independently increased the risk of cardiac mortality for a localized ipsilateral breast tumour relapse.

Objectif de l’étude

La chirurgie conservatrice du sein suivie d’une réirradiation pour une rechute localisée d’une tumeur du sein homolatérale peut augmenter la dose délivrée au cœur et entraîner théoriquement un risque plus élevé de toxicité cardiaque. Cette étude visait à comparer l’incidence de la mortalité cardiaque chez les patientes prises en charge pour une tumeur du sein homolatérale, soit par chirurgie conservatrice du sein suivie d’une réirradiation, soit par mastectomie

目的:保乳手术后再照射治疗局部同侧乳腺肿瘤复发可能会增加心脏的放射剂量,导致心脏不良事件的风险增加。本研究旨在比较2000年至2020年期间因局部同侧乳腺肿瘤复发而接受保乳手术后再照射或全乳房切除术治疗的患者的心脏死亡发生率:在监测、流行病学和最终结果(SEER)项目数据库中确定了所有接受保乳手术和辅助放疗治疗的原发性非转移性乳腺癌患者,并纳入了接受保乳手术和再照射("BCS+ReRT "组,n=239)或全乳切除术("TM "组,n=3127)治疗后局部同侧乳腺肿瘤复发的患者。主要目的是比较接受保乳手术后再照射和全乳房切除术的患者的心脏死亡率。次要终点是总生存率和癌症特异性生存率:结果:接受保乳手术后再照射治疗的患者心脏死亡率明显更高(危险比 [HR]:2.40,95% 置信区间 [95%CI]:1.19-4.86,P<0.05):在单变量分析中,危险比[HR]:2.40,95% 置信区间[95% CI]:1.19-4.86,P=0.006);在多变量分析中,调整年龄、侧位和化疗因素后,观察到差异无统计学意义(HR:1.96,95% CI:0.96-3.94,P=0.067),年龄是唯一的混杂因素。与接受全乳房切除术的患者相比,接受保乳手术后再放疗的患者总生存率较低,这在统计学上无显著差异(HR:1.37,95% CI:0.98-1.90,P=0.066),而在癌症特异性生存率方面未观察到差异(HR:1.01,95% CI:0.56-1.82,P=0.965):在这项研究中,心脏死亡的发生率较低,保乳手术后再放疗并不会单独增加同侧局部乳腺肿瘤复发的心脏死亡风险。
{"title":"Survival and toxicity after breast-conserving surgery and external beam reirradiation for localized ipsilateral breast tumour recurrence: A population-based study","authors":"P. Loap,&nbsp;A. Fourquet,&nbsp;Y. Kirova","doi":"10.1016/j.canrad.2024.03.001","DOIUrl":"10.1016/j.canrad.2024.03.001","url":null,"abstract":"<div><h3>Purpose</h3><p>Breast-conserving surgery followed by reirradiation for a localized ipsilateral breast tumour relapse may increase the radiation dose delivered to the heart and result in a greater risk of cardiac adverse events. This study aimed to compare the incidence of cardiac mortality in patients treated for a localized ipsilateral breast tumour relapse, either with breast-conserving surgery followed by reirradiation or with total mastectomy between 2000 and 2020.</p></div><div><h3>Materials and methods</h3><p>All patients treated for a primary non-metastatic breast cancer with breast-conserving surgery and adjuvant radiotherapy were identified in the Surveillance, Epidemiology, and End Results (SEER) program database, and those who subsequently experienced a localized ipsilateral breast tumour relapse treated with breast-conserving surgery and reirradiation (“BCS<!--> <!-->+<!--> <!-->ReRT” group, <em>n</em> <!-->=<!--> <!-->239) or with total mastectomy (“TM” group, <em>n</em> <!-->=<!--> <!-->3127) were included. The primary objective was to compare the cardiac mortality rate between the patients who underwent breast-conserving surgery followed by reirradiation and total mastectomy. Secondary endpoints were overall survival and cancer specific survival.</p></div><div><h3>Results</h3><p>Cardiac mortality was significantly higher in patients treated with breast-conserving surgery followed by reirradiation (hazard ratio [HR]: 2.40, 95% confidence interval [95% CI]: 1.19–4.86, <em>P</em> <!-->=<!--> <!-->0.006) in univariate analysis; non-statistically significant differences were observed after adjusting for age, laterality and chemotherapy on multivariate analysis (HR: 1.96, 95% CI: 0.96–3.94, <em>P</em> <!-->=<!--> <!-->0.067), age being the only confounding factor. A non-statistically significant difference towards lower overall survival was observed in patients who had breast-conserving surgery followed by reirradiation compared with those who underwent total mastectomy (HR: 1.37, 95% CI: 0.98–1.90, <em>P</em> <!-->=<!--> <!-->0.066), and no differences were observed in terms of cancer specific survival (HR: 1.01, 95% CI: 0.56–1.82, <em>P</em> <!-->=<!--> <!-->0.965).</p></div><div><h3>Conclusion</h3><p>In this study, the incidence of cardiac mortality was low, and breast-conserving surgery followed by reirradiation did not independently increased the risk of cardiac mortality for a localized ipsilateral breast tumour relapse.</p></div><div><h3>Objectif de l’étude</h3><p>La chirurgie conservatrice du sein suivie d’une réirradiation pour une rechute localisée d’une tumeur du sein homolatérale peut augmenter la dose délivrée au cœur et entraîner théoriquement un risque plus élevé de toxicité cardiaque. Cette étude visait à comparer l’incidence de la mortalité cardiaque chez les patientes prises en charge pour une tumeur du sein homolatérale, soit par chirurgie conservatrice du sein suivie d’une réirradiation, soit par mastectomie ","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141428513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Myonecrosis as a rare side effect of stereotactic body radiotherapy for bone metastases: Report of two cases and a comprehensive literature review 骨转移立体定向体放射治疗的罕见副作用--肌坏死:两例病例的报告和全面的文献综述。
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-06-01 DOI: 10.1016/j.canrad.2023.10.001
C. Atahan , G. Ugurluer , B. Kumbasar , E. Ozyar , B. Atalar

Stereotactic body radiotherapy is a highly effective form of radiation therapy for palliation of bone metastases, but it can also lead to rare but severe side effects, such as myonecrosis. According to the literature, the incidence of myonecrosis after stereotactic body radiotherapy is low and mostly dose dependent. It is crucial to consider the potential impact of immunotherapy and other systemic therapies in the assessment. The course of radiation myonecrosis can vary, and corticosteroids or vascular endothelial growth factor inhibitors may potentially play a role in its treatment. Herein, we report two patients presenting with myonecrosis after stereotactic body radiotherapy for bone metastasis.

立体定向体放射治疗是一种用于缓解骨转移的高效放射治疗方式,但也可能导致罕见但严重的副作用,如肌坏死。根据文献记载,立体定向体放射治疗后发生肌坏死的几率很低,而且主要取决于剂量。在进行评估时,必须考虑免疫疗法和其他系统疗法的潜在影响。放射性肌坏死的病程可能会有所不同,皮质类固醇或血管内皮生长因子抑制剂可能会在治疗中发挥作用。在此,我们报告了两名因骨转移接受立体定向体放射治疗后出现肌坏死的患者。
{"title":"Myonecrosis as a rare side effect of stereotactic body radiotherapy for bone metastases: Report of two cases and a comprehensive literature review","authors":"C. Atahan ,&nbsp;G. Ugurluer ,&nbsp;B. Kumbasar ,&nbsp;E. Ozyar ,&nbsp;B. Atalar","doi":"10.1016/j.canrad.2023.10.001","DOIUrl":"10.1016/j.canrad.2023.10.001","url":null,"abstract":"<div><p>Stereotactic body radiotherapy is a highly effective form of radiation therapy for palliation of bone metastases, but it can also lead to rare but severe side effects, such as myonecrosis. According to the literature, the incidence of myonecrosis after stereotactic body radiotherapy is low and mostly dose dependent. It is crucial to consider the potential impact of immunotherapy and other systemic therapies in the assessment. The course of radiation myonecrosis can vary, and corticosteroids or vascular endothelial growth factor inhibitors may potentially play a role in its treatment. Herein, we report two patients presenting with myonecrosis after stereotactic body radiotherapy for bone metastasis.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141422131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast cancer in a transgender man and hypofractionated radiotherapy: A case report and review of literature 变性人乳腺癌与低分次放射治疗:病例报告和文献综述。
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-06-01 DOI: 10.1016/j.canrad.2023.08.011
A. Bennassi , E. Rivin Del Campo , C. Théodore , F. Huguet

A 77-year-old transgender man (assigned female sex at birth, gender identity male, i.e. female-to-male) was referred for a palpable mass of the right chest wall. Biopsies revealed invasive lobular breast carcinoma. After discussion by a multidisciplinary tumour board meeting, the patient was treated with total mastectomy, adjuvant hypofractionated radiation therapy, and hormone therapy. At 1.5-year follow-up, there was no sign of recurrence or long-term radiation side effects. To our knowledge, this is the first reported case of adjuvant hypofractionated radiation therapy in a transgender patient with breast cancer.

一名 77 岁的变性男子(出生时被指定为女性,性别认同为男性,即女变男)因右胸壁可触及肿块而转诊。活检结果显示为浸润性乳腺小叶癌。经多学科肿瘤委员会会议讨论后,患者接受了全乳切除术、辅助低分次放射治疗和激素治疗。在 1.5 年的随访中,没有发现复发迹象或长期放射副作用。据我们所知,这是第一例变性乳腺癌患者接受辅助低分次放射治疗的报道。
{"title":"Breast cancer in a transgender man and hypofractionated radiotherapy: A case report and review of literature","authors":"A. Bennassi ,&nbsp;E. Rivin Del Campo ,&nbsp;C. Théodore ,&nbsp;F. Huguet","doi":"10.1016/j.canrad.2023.08.011","DOIUrl":"10.1016/j.canrad.2023.08.011","url":null,"abstract":"<div><p>A 77-year-old transgender man (assigned female sex at birth, gender identity male, i.e. female-to-male) was referred for a palpable mass of the right chest wall. Biopsies revealed invasive lobular breast carcinoma. After discussion by a multidisciplinary tumour board meeting, the patient was treated with total mastectomy, adjuvant hypofractionated radiation therapy, and hormone therapy. At 1.5-year follow-up, there was no sign of recurrence or long-term radiation side effects. To our knowledge, this is the first reported case of adjuvant hypofractionated radiation therapy in a transgender patient with breast cancer.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141263307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Radiotherapie
全部 Geobiology Appl. Clay Sci. Geochim. Cosmochim. Acta J. Hydrol. Org. Geochem. Carbon Balance Manage. Contrib. Mineral. Petrol. Int. J. Biometeorol. IZV-PHYS SOLID EART+ J. Atmos. Chem. Acta Oceanolog. Sin. Acta Geophys. ACTA GEOL POL ACTA PETROL SIN ACTA GEOL SIN-ENGL AAPG Bull. Acta Geochimica Adv. Atmos. Sci. Adv. Meteorol. Am. J. Phys. Anthropol. Am. J. Sci. Am. Mineral. Annu. Rev. Earth Planet. Sci. Appl. Geochem. Aquat. Geochem. Ann. Glaciol. Archaeol. Anthropol. Sci. ARCHAEOMETRY ARCT ANTARCT ALP RES Asia-Pac. J. Atmos. Sci. ATMOSPHERE-BASEL Atmos. Res. Aust. J. Earth Sci. Atmos. Chem. Phys. Atmos. Meas. Tech. Basin Res. Big Earth Data BIOGEOSCIENCES Geostand. Geoanal. Res. GEOLOGY Geosci. J. Geochem. J. Geochem. Trans. Geosci. Front. Geol. Ore Deposits Global Biogeochem. Cycles Gondwana Res. Geochem. Int. Geol. J. Geophys. Prospect. Geosci. Model Dev. GEOL BELG GROUNDWATER Hydrogeol. J. Hydrol. Earth Syst. Sci. Hydrol. Processes Int. J. Climatol. Int. J. Earth Sci. Int. Geol. Rev. Int. J. Disaster Risk Reduct. Int. J. Geomech. Int. J. Geog. Inf. Sci. Isl. Arc J. Afr. Earth. Sci. J. Adv. Model. Earth Syst. J APPL METEOROL CLIM J. Atmos. Oceanic Technol. J. Atmos. Sol. Terr. Phys. J. Clim. J. Earth Sci. J. Earth Syst. Sci. J. Environ. Eng. Geophys. J. Geog. Sci. Mineral. Mag. Miner. Deposita Mon. Weather Rev. Nat. Hazards Earth Syst. Sci. Nat. Clim. Change Nat. Geosci. Ocean Dyn. Ocean and Coastal Research npj Clim. Atmos. Sci. Ocean Modell. Ocean Sci. Ore Geol. Rev. OCEAN SCI J Paleontol. J. PALAEOGEOGR PALAEOCL PERIOD MINERAL PETROLOGY+ Phys. Chem. Miner. Polar Sci. Prog. Oceanogr. Quat. Sci. Rev. Q. J. Eng. Geol. Hydrogeol. RADIOCARBON Pure Appl. Geophys. Resour. Geol. Rev. Geophys. Sediment. Geol.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1